Insys Therapeutics sees revenue from Subsys at $61-$62 million; shares plunge 21%

pharmafile | April 11, 2016 | News story | Business Services, Manufacturing and Production, Sales and Marketing Insys Therapeutics, Stock Price, Subsys, opioids, pain drug 

Insys Therapeutics Inc (Nasdaq: INSY) stock plunged nearly 21% Monday after the company said sales for its pain drug will be impacted by a decline in demand.

The company forecast first-quarter revenue from Subsys (fentanyl sublingual spray) in the range of $61 million to $62 million saying the figures reflect a decline in demand on the back of lower prescription for the therapy.

The company reported total revenue of $70.77 million for the same period last year.

Insys said prescription volumes for Subsys were down along with wholesale inventory. The drop in wholesale channel inventory is estimated at $7 million. However, the company said it sees subsys prescription decline is close to stabilizing.

The drug maker attributed the drop to heightened publicity around opioid epidemic, which has led to sensitivity by some healthcare providers to prescribe opioids.

Insys believes it will remain profitable at current sales levels and intends to pursue all of its research and development projects.

Anjali Shukla

Related Content

FDA accepts new drug application for Orexo’s opioid overdose medication

Orexo has announced that its New Drug Application (NDA) for OX124 has been accepted for …

FDA approves a second OTC naloxone nasal spray

The US Food and Drug Administration (FDA) has announced that it has approved RiVive, 3mg …

FDA approves prescription nasal spray for opioid overdose treatment

The US Food and Drug Administration (FDA) has announced that it has approved Opvee, the …

Latest content